CD20 is a potential target for the treatment of leukemia, lymphoma, and some autoimmune diseases. However, due to the complexity of expression and the unstable bioactivity, it is very hard to find an appropriate CD20 protein on the market for detecting the CD20-CAR expression and the bioactivity of antibody drugs.
To tackle these challenges, ACROBiosystems has designed the full-length multi-transmembrane CD20 proteins, produced by HEK293 cells and insect cells. The bioactivity and purity of the full-length CD20 protein were confirmed by ELISA, SDS-PAGE, and SPR. In addition, ACROBiosystems provides full-length CD20 protein for immunization and assessment of CD20-CAR expression.
Application
Product List
| Molecule |
Cat. No. |
Host |
Product Description |
| CD20/ MS4A1 |
CD0-H52H3 |
HEK293 |
Human CD20/ MS4A1 Full Length Protein, His Tag |
| CD0-H55Ha |
Insect cells-HI5 |
Human CD20/ MS4A1 Full Length Protein, His Tag |
Product Features
Full-length CD20 protein fully complies with both small and big loops.
Full-length CD20 protein has better bioactivity.
- HEK293 Cell (Full Length)
Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–16 ng/mL.
- Insect Cell (Full Length)
Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 1–16 ng/mL.
- Escherichia coli (Extracellular)
Immobilized Rituximab at 5 μg/mL (100 μL/well) can bind Human CD20, TrxA Tag, His Tag (E. coli) with a linear range of 78–2500 ng/mL.
The bioactivity of Full-Length CD20 Protein was verified by Elisa/SPR and the protocols are presented.
ELISA
Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression) and Cat. No. CD0-H55Ha (Insect cells expression).
Immobilized Ofatumumab at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–31 ng/mL.
Immobilized Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) at 2 μg/mL (100 μL/well) on Nickel Coated Plate, can bind Rituximab with a linear range of 0.313–1.25 μg/mL.
Immobilized Ofatumumab (Human IgG1) at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 2–31 ng/mL.
SPR
Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression) and Cat. No. CD0-H55Ha (Insect cells expression).
MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 1.77 nM as determined in an SPR assay (Biacore T200).
Ofatumumab (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 3.57 nM as determined in an SPR assay (Biacore T200).
MabThera® (Rituximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 1.21 nM as determined in an SPR assay (in presence of DDM) (Biacore T200).
Ofatumumab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 2.977 nM as determined in an SPR assay (Biacore T200).
About ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application oriented development strategy, with a particular focus on product design, quality control and solution based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.
To respond to coronavirus pandemic, ACROBiosystems has developed SARS-CoV-2 antigens specifically designed and optimized for serological test kits, including Spike-derived antigen S1, RBD and Nucleocapsid protein. Proteins have been supplied to diagnostic companies in large quantity.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.